Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.57 |
| ▸ | HTR1A | P08908 | 7/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538522 | 0.94 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL29966 | 0.91 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL9957545 | 0.84 | SLC6A2 (0.44) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL15294475 | 0.84 | MCHR1 (0.52) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL18186077 | 0.82 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL12181083 | 0.82 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL234010 | 0.82 | SLC6A2 (0.81) | SLC6A2HTR1ASLC6A3SLC6A4HTR2C | |
| SCHEMBL16571016 | 0.82 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| SCHEMBL2298389 | 0.82 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3LPAR1LPAR5 | |
| Hydrochloric Acid SCHEMBL3466964 | 0.81 | SLC6A2 (0.79) | SLC6A2HTR1ASLC6A3SLC6A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | SLC6A2 2764/4885HTR1A 830/4885SLC6A3 3030/4885 |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | SLC6A2 903/4885HTR1A 1281/4885SLC6A3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.